NYSE · Healthcare · Diagnostics & Research · USA
Waters Corp is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Waters Corp designs, manufactures and services analytical instruments and software, including liquid chromatography and mass spectrometry systems for chemical analysis, plus thermal analysis instruments. The company serves customers in pharmaceutical, clinical, life sciences, industrial, environmental and academic sectors. Following an acquisition of biosciences and diagnostic businesses, Waters also offers specimen collection systems, infectious disease detection instruments and flow cytometry products.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Waters Corp stock.
Overvalued: intrinsic value $127.21 per share, market price $434.27, margin of safety -241.4% (as of 2026-10-19).
Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $127.21; the price of $434.27 is 241% above that value, and 71% of that value comes from beyond year five.
Leak Score: 38/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
14 more in this industry show a wider margin of safety.
WAT is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $127.21; the price of $434.27 is 241% above that value, and 71% of that value comes from beyond year five.
$127.21 per share (as of the 2026-10-19 close), against a market price of $434.27. That is a margin of safety of -241.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
38 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.